Clift Norris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Clift Norris has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Han Liang
Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
1 shared publication - Hoang Q. Nguyen
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
1 shared publication - John J Venier
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
1 shared publication - Kam-Wah Tsui
Department of Statistics, University of Wisconsin - Madison, Madison, WI 53792, USA
1 shared publication - Peter F. Thall
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
1 shared publication - Richard C. Herrick
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
1 shared publication
Latest Publications
- 1 September 2014
- Published by SAGE Publications in Clinical Trials
- Vol. 11 (6) , 657-666
Effective sample size for computing prior hyperparameters in Bayesian phase I–II dose-finding
Background: The efficacy–toxicity trade-off based design is a practical Bayesian phase I–II dose-finding methodology. Because the design’s performance is very sensitive to prior hyperparameters and the shape of the target trade-off contour, specifying these two design elements properly is essential. Purpose: The goals are to provide a method that uses elicited mean outcome probabilities to derive a prior that is neither overly informative nor overly disperse, and practical guidelines for specifying the target trade-off contour. Methods: A general algorithm is presented that determines prior hyperparameters using least squares penalized by effective sample size. Guidelines for specifying the trade-off contour are provided. These methods are illustrated by a clinical trial in advanced prostate cancer. A new version of the efficacy–toxicity program is provided for implementation. Results: Together, the algorithm and guidelines provide substantive improvements in the design’s operating characteristics. Limitations: The method requires a substantial number of elicited values and design parameters, and computer simulations are required to obtain an acceptable design. Conclusion: The two key improvements greatly enhance the efficacy–toxicity design’s practical usefulness and are straightforward to implement using the updated computer program. The algorithm for determining prior hyperparameters to ensure a specified level of informativeness is general, and may be applied to models other than that underlying the efficacy–toxicity method.
- 1 September 2014
- Published by SAGE Publications in Clinical Trials
- Vol. 11 (6) , 657-666
Effective sample size for computing prior hyperparameters in Bayesian phase I–II dose-finding
Background: The efficacy–toxicity trade-off based design is a practical Bayesian phase I–II dose-finding methodology. Because the design’s performance is very sensitive to prior hyperparameters and the shape of the target trade-off contour, specifying these two design elements properly is essential. Purpose: The goals are to provide a method that uses elicited mean outcome probabilities to derive a prior that is neither overly informative nor overly disperse, and practical guidelines for specifying the target trade-off contour. Methods: A general algorithm is presented that determines prior hyperparameters using least squares penalized by effective sample size. Guidelines for specifying the trade-off contour are provided. These methods are illustrated by a clinical trial in advanced prostate cancer. A new version of the efficacy–toxicity program is provided for implementation. Results: Together, the algorithm and guidelines provide substantive improvements in the design’s operating characteristics. Limitations: The method requires a substantial number of elicited values and design parameters, and computer simulations are required to obtain an acceptable design. Conclusion: The two key improvements greatly enhance the efficacy–toxicity design’s practical usefulness and are straightforward to implement using the updated computer program. The algorithm for determining prior hyperparameters to ensure a specified level of informativeness is general, and may be applied to models other than that underlying the efficacy–toxicity method.
- Open Access
- 17 December 2012
- Published by Springer Nature in BMC Genomics
- Vol. 13 (S8) , S9
BM-Map: an efficient software package for accurately allocating multireads of RNA-sequencing data
Background: RNA sequencing (RNA-seq) has become a major tool for biomedical research. A key step in analyzing RNA-seq data is to infer the origin of short reads in the source genome, and for this purpose, many read alignment/mapping software programs have been developed. Usually, the majority of mappable reads can be mapped to one unambiguous genomic location, and these reads are called unique reads. However, a considerable proportion of mappable reads can be aligned to more than one genomic location with the same or similar fidelities, and they are called "multireads". Allocating these multireads is challenging but critical for interpreting RNA-seq data. We recently developed a Bayesian stochastic model that allocates multireads more accurately than alternative methods (Ji et al. Biometrics 2011). Results: In order to serve a greater biological community, we have implemented this method in a stand-alone, efficient, and user-friendly software package, BM-Map. BM-Map takes SAM (Sequence Alignment/Map), the most popular read alignment format, as the standard input; then based on the Bayesian model, it calculates mapping probabilities of multireads for competing genomic loci; and BM-Map generates the output by adding mapping probabilities to the original SAM file so that users can easily perform downstream analyses. The program is available in three common operating systems, Linux, Mac and PC. Moreover, we have built a dedicated website, http://bioinformatics.mdanderson.org/main/BM-Map, which includes free downloads, detailed tutorials and illustration examples. Conclusions: We have developed a stand-alone, efficient, and user-friendly software package for accurately allocating multireads, which is an important addition to our previous methodology paper. We believe that this bioinformatics tool will greatly help RNA-seq and related applications reach their full potential in life science research.
- 17 December 2012
- Published by Springer Nature in BMC Genomics
- Vol. 13 (S8) , S9
Open AccessBM-Map: an efficient software package for accurately allocating multireads of RNA-sequencing data
Background: RNA sequencing (RNA-seq) has become a major tool for biomedical research. A key step in analyzing RNA-seq data is to infer the origin of short reads in the source genome, and for this purpose, many read alignment/mapping software programs have been developed. Usually, the majority of mappable reads can be mapped to one unambiguous genomic location, and these reads are called unique reads. However, a considerable proportion of mappable reads can be aligned to more than one genomic location with the same or similar fidelities, and they are called "multireads". Allocating these multireads is challenging but critical for interpreting RNA-seq data. We recently developed a Bayesian stochastic model that allocates multireads more accurately than alternative methods (Ji et al. Biometrics 2011). Results: In order to serve a greater biological community, we have implemented this method in a stand-alone, efficient, and user-friendly software package, BM-Map. BM-Map takes SAM (Sequence Alignment/Map), the most popular read alignment format, as the standard input; then based on the Bayesian model, it calculates mapping probabilities of multireads for competing genomic loci; and BM-Map generates the output by adding mapping probabilities to the original SAM file so that users can easily perform downstream analyses. The program is available in three common operating systems, Linux, Mac and PC. Moreover, we have built a dedicated website, http://bioinformatics.mdanderson.org/main/BM-Map, which includes free downloads, detailed tutorials and illustration examples. Conclusions: We have developed a stand-alone, efficient, and user-friendly software package for accurately allocating multireads, which is an important addition to our previous methodology paper. We believe that this bioinformatics tool will greatly help RNA-seq and related applications reach their full potential in life science research.